Medicare Enrolled
Dr. Maria Theodoulou, MD
Medical Oncology · Albany, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Theodoulou from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Theodoulou?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Theodoulou
Dr. Maria Theodoulou is a medical oncology specialist in Albany, NY, with 19 years of NPI registration. Based on federal Medicare data, Dr. Theodoulou performed 15,907 Medicare services across 2,342 unique beneficiaries.
Between the years covered by Open Payments, Dr. Theodoulou received a total of $1,056,111 from 13 pharmaceutical and/or device companies across 586 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Theodoulou is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 6% volume in NY
$1,056,111 industry payments
Medicare Practice Summary
Medicare Utilization ↗15,907
Medicare services
Top 6% in NY for medical oncology
2,342
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~837 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
7,500 | $0 | $6 |
| Denosumab injection (Prolia/Xgeva) | 2,940 | $19 | $58 |
| Anti-nausea injection (Aloxi/palonosetron) | 670 | $1 | $114 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
660 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
560 | $8 | $18 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
541 | $8 | $34 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
524 | $10 | $60 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
285 | $19 | $93 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 280 | $20 | $120 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
250 | $93 | $217 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
205 | $16 | $76 |
| Vitamin D level test A blood test to measure the amount of Vitamin D-3 in your body. |
148 | $29 | $250 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
140 | $13 | $95 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
133 | $63 | $144 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
131 | $24 | $138 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
129 | $111 | $622 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
109 | $11 | $84 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
73 | $61 | $186 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
69 | $13 | $56 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
60 | $9 | $52 |
| Iron level test | 47 | $6 | $25 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
47 | $23 | $141 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
46 | $27 | $128 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
45 | $9 | $33 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
35 | $53 | $303 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
32 | $51 | $276 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
31 | $6 | $29 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
30 | $4 | $20 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
30 | $6 | $32 |
| Immunoassay substance measurement A laboratory test that uses immunoassay techniques to measure the level of a specific substance in a sample. |
28 | $17 | $181 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
22 | $7 | $27 |
| New patient office visit, complex (60-74 min) | 22 | $178 | $419 |
| Lipid panel (cholesterol and triglycerides) A blood test that measures cholesterol and triglyceride levels. |
19 | $13 | $76 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
14 | $1,226 | $4,981 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
14 | $140 | $275 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 14 | $414 | $638 |
| Vitamin B-12 level test A blood test that measures the amount of vitamin B-12 in your body. |
12 | $15 | $72 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
12 | $62 | $140 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.1% high complexity
76.7% medium
21.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,056,111
Total received (2018-2024)
Avg $150,873/year across 7 years
Top 1% in NY for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
13
Companies
586
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$990,835 (93.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$64,055 (6.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,220 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$205,528
2023
$245,807
2022
$174,307
2021
$62,633
2020
$92,827
2019
$147,255
2018
$127,754
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$88,302
Daiichi Sankyo Inc.
$75,154
Gilead Sciences, Inc.
$31,293
PUMA BIOTECHNOLOGY, INC.
$5,739
Novartis Pharmaceuticals Corporation
$3,004
Stemline Therapeutics Inc.
$1,860
Coherus Biosciences Inc.
$142
PFIZER INC.
$33
Top 3 companies account for 94.8% of 2024 payments
All-time payments by company (2018-2024) ›
Genentech USA, Inc.
$262,780
Daiichi Sankyo Inc.
$226,817
AstraZeneca Pharmaceuticals LP
$161,355
Seagen Inc.
$130,717
Puma Biotechnology, Inc.
$128,751
PUMA BIOTECHNOLOGY, INC.
$47,608
PFIZER INC.
$36,500
Gilead Sciences, Inc.
$34,572
Stemline Therapeutics Inc.
$13,219
Novartis Pharmaceuticals Corporation
$10,860
Coherus Biosciences Inc.
$2,015
GE HEALTHCARE
$889
Incyte Corporation
$27
Top 3 companies account for 61.6% of all-time payments
Associated products mentioned in payments ›
AFINITOR · ENHERTU · Enhertu · Herceptin · IBRANCE · JAKAFI · KISQALI · Kadcyla · NERLYNX · Nerlynx · Orserdu · PIQRAY · Perjeta · Phesgo · TALZENNA · TECENTRIQ · TUKYSA · Trodelvy · Udenyca
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for medical oncology in NY.
Geographic Context
Medical oncologists within 10 mi
7
Per 100K population
2.2
County median income
$83,149
Nearest hospital
ALBANY MEDICAL CENTER HOSPITAL
2.0 mi
2.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Theodoulou is a mixed practice specialist, with above-average Medicare volume (top 6% in NY), with speaking/promotional industry engagement in the top 1% of NY peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Theodoulou experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Theodoulou performed 7,500 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Theodoulou receive payments from pharmaceutical companies?
Yes. Dr. Theodoulou received a total of $1,056,111 from 13 companies across 586 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Theodoulou's costs compare to other medical oncologists in Albany?
Dr. Theodoulou's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Theodoulou) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Albany
Browse medical oncologists in Albany ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in NY
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in NY
Which NY medical oncologists receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology